Teva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of Schizophrenia in Adults
April 28, 2023
April 28, 2023
MedinCell’s partner Teva today announced refiling for approval of mdc-IRM and confirmed planned launch in the U.S. in H1 2023
November 3, 2022
November 3, 2022
MedinCell’s partner Teva confirms expectation for approval and commercialization in the US in H1 2023 for mdc-IRM/TEV46000
July 27, 2022
July 27, 2022
MedinCell’s partner Teva provides additional information regarding the New Drug Application for mdc-IRM
May 3, 2022
May 3, 2022
MedinCell provides additional information regarding the new drug application for mdc-IRM
April 19, 2022
April 19, 2022
Teva and MedinCell Receive Complete Response Letter for TV-46000/mdc-IRM
Phase 3 data of mdc-IRM, first product based on MedinCell’s technology, shows significant improvements in patients with schizophrenia: – Prolonged time to impending relapse – Decreased risk of relapse – Increased chance of clinical stability
